Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

LONDON, Nov 7 — Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday.

Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...

Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...

Novo’s obesity drug sales nearly doubled outside the U.S. during the quarter as global demand continued to rise.

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Novo Nordisk A/S NVO is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide and cagrilintide and aims to reduce weight by 25% without added side effects.